GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

GSK is a leading biopharmaceutical company with a focus on vaccines and products for major diseases. GSK's drug line-up is safe and profitable, with competitors facing larger sales loss exposure due ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX -0.28% rising 0.44% to 10,697.57.

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the October 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain ...

GSK stock in London traded around 1,858.5 pence on September 15, 2026 after the company agreed a deal worth up to USD 750 million for a blood cancer drug. Berenberg raised its rating to Buy and lifted ...

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain for ...

Harvey Jones backed the GSK share price to spring into life a couple of years ago, but it's still struggling to make headway. Why isn't it doing better? The post Trading below levels seen 25 years ago ...